Clinical Trial Update: Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration [Phase 4]

View source ↗

Summary

Phase 4 trial update for aflibercept in wet age-related macular degeneration (wet AMD) from the Japanese Treat and Extend study; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Bayer | Conditions: Wet Macular Degeneration | Phase 4 | Status: COMPLETED | Results posted: 2018-03-12